Sarcoma  >>  Lartruvo (olaratumab)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lartruvo (olaratumab) / Eli Lilly
ANNOUNCE, NCT02451943 / 2015-000134-30: A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma

Active, not recruiting
3
509
Europe, Canada, Japan, US, RoW
Olaratumab, LY3012207, Doxorubicin, Placebo
Eli Lilly and Company
Soft Tissue Sarcoma
12/18
07/24

Download Options